Clinical Trial Update: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating CSL511 fibrinogen concentrate in patients with pseudomyxoma peritonei undergoing cytoreductive surgery to manage acquired fibr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Fibrinogen Deficiency
• Pseudomyxoma Peritonei

Drugs mentioned

• CSL511 Fibrinogen Concentrate (fibrinogen concentrate (human))

Snippet

Sponsor: CSL Behring | Conditions: Acquired Fibrinogen Deficiency | Phase 3 | Status: RECRUITING